Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Description

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Conditions

Baseline Thrombocytopenia

Talk to us

Study Overview

On this page

Study Details

Study overview

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Condition
Baseline Thrombocytopenia
Intervention / Treatment

-

Contacts and Locations

Dallas

Methodist Dallas Medical Center, Dallas, Texas, United States, 75203

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥ 18 years
  • * PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
  • * Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
  • * At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
  • * Death within 48 hours post-PCI
  • * DAPT prior to cardiac catheterization

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Methodist Health System,

Jessica Rago Crotty, Pharm D, PRINCIPAL_INVESTIGATOR, Methodist Midlothian Medical Center

Study Record Dates

2024-08-22